Efficacy of aztreonam in the treatment of neonatal sepsis.
In Greece the majority of infections that affect the neonatal population are caused by gram-negative bacteria rather than by group B streptococci as in the United States. The present study investigated the efficacy of aztreonam, a beta-lactam antibiotic that is effective against gram-negative organisms, in this population. Fifty-five neonates aged 2 hours to 36 days who had sepsis were enrolled in this open study. Laboratory tests were extensive, and follow-ups were detailed. Aztreonam (90-125 mg/[kg.d]) administered in two or three doses was given in combination with penicillin (100,000 U/[kg.d]) for 6-15 days. Fifty-two infants were cured, one improved, and two did not improve and received other, more effective regimens. Adverse effects were minimal, and tolerance of aztreonam was excellent.
Sklavunu-Tsurutsoglu
S
S
Second Department of Pediatrics, Aristotelian University, AHEPA Hospital, Thessaloniki, Greece.
Gatzola-Karaveli
M
M
Hatziioannidis
K
K
Tsurutsoglu
G
G
D001398:Aztreonam / Q000009:adverse effects / Q000627:therapeutic use*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy*
D001398:Aztreonam